Latest Conference Coverage

Diagnosis Through Teleneurology: Jason Poon, MD

The neurologist at University of Utah discussed the potential of using teleneurology to diagnose neurological conditions.

Data-Driven Categorization of Patients With Multiple Sclerosis: Daniel Ontaneda, MD, PhD

The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the findings of his presentation at AAN 2021.

NeuroVoices: Vineet Punia, MD, MS, on Responsive Neurostimulation in Older Adults

The neurologist from Cleveland Clinic discussed his study presented at AAN 2021 involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.

Understanding Fenfluramine’s Impact on Executive Function in Lennox-Gastaut Syndrome

Kim Bishop, PhD, and Arnold Gammaitoni, PharmD, discussed the ways fenfluramine impacts not only seizure frequency, but executive function in individuals with Lennox-Gastaut syndrome.

Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhD

The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.

Biomechanical Measures of Upper Extremity Function in MS: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic spoke to a study using the digital Manual Dexterity Test.

Dyskinesia and OFF Time Disruptions Seen in Most Patients with Parkinson Disease

A survey of more than 500 individuals also found that dyskinesia impacted social interactions and reported that OFF time was isolating.

Lower Sodium Oxybate for Narcolepsy: Nancy Foldvary-Schaefer, DO, MS

The director of the sleep disorders center at Cleveland Clinic discussed her investigations into low-sodium oxybate presented at AAN 2021.

Improving Social Determinants of Health May Improve Epilepsy Treatment Outcomes

The professor of neurology at Mayo Clinic discussed the effects social determinants of health can have on epilepsy treatment outcomes and where research needs to turn to next.

Further Research on Pimavanserin: Clive Ballard, MD

The dean at the University of Exeter Medical School discussed ongoing studies of pimavanserin and his thoughts on the FDA’s actions related to the agent.

Mechanism of Action of Nipocalimab in Myasthenia Gravis: Jeffrey Guptill, MD, MS, MHS

The associate professor of neurology and neurologist at Duke University provided insight on the unique mechanism of nipocalimab and its effect on patients with myasthenia gravis.

Advantages of IMU-838 Over Teriflunomide for MS: Robert Fox, MD

The Vice-Chair for Research at the Cleveland Clinic Neurological Institute discussed topline results from the EMPhASIS trial of IMU-838.

Episode 35: Highlights From the AAN Annual Meeting

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

Advantages of MANAGE-PD Screening Tool: Hubert Fernandez, MD

The director of the Center for Neurological Restoration at Cleveland Clinic provided an inside perspective on how the MANAGE-PD tool can effectively assist in the Parkinson disease screening process.

Multiple Sclerosis Performance Test Battery: Stephen Rao, PhD, ABPP-Cn

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic, outlined the different tests that make up the MSPT battery.

Atogepant’s Impact on Patient-Reported Outcomes: Lawrence Severt, MD, PhD

The director at AbbVie discussed a subgroup analysis of the phase 3 ADVANCE study of atogepant in patients with migraine and its benefit on patient-reported outcome measures.

Assessing When to Take a Nonoral Approach to Migraine: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center spoke to the considerations she makes in determining when patients with migraine may need a nonoral therapy to address their disease.

NeuroVoices: Neal Parikh, MD, MS, on Racial Disparities in Post-Stroke Smoking Cessation

The assistant professor of neurology at the Weill Cornell Brain and Spine Center discussed his presentation at AAN 2021 evaluating racial disparities in smoking cessation among stroke survivors.

Providing Nonoral Migraine Care With Intranasal DHE: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center spoke to the efficacy and application of a new formulation of the longstanding agent dihydroergotamine in the treatment of migraine.

AHS Members Are Comfortable With Treating Migraine Via Telehealth

In addition to a number of positive attributes stemming from telehealth use, most providers claimed they were interested in digitally prescribing headache apps and remotely monitoring patient symptoms.

Studying the Trajectory of Cognitive Decline: Richard Gershon, PhD

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed how the cognitive mobile toolbox can be used to assess cognition in all populations.

Lenalidomide Demonstrates Safety in Anti-MAG Neuropathy

Three patients included in the study showed positive trends across both I-RODS and Jamar grip strength following treatment with lenalidomide.

Addressing Specific Social Determinants of Health in Epilepsy: Joseph Sirven, MD

The professor of neurology at Mayo Clinic detailed ways to address social determinants of health and the gaps in care for patients with epilepsy.

Natalizumab Improves Social and Mental Health in Patients with Multiple Sclerosis

Researchers compared Neuro-QoL scores between patients treated with natalizumab and ocrelizumab, another high-efficacy treatment for MS.

The Long-Term Efficacy of Inebilizumab in NMOSD: Bruce Cree, MD, PhD, MAS

The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.

Fenfluramine Improves Executive Function in Lennox-Gastaut Syndrome

Improvement was statistically significant for Cognition and the Global Executive Composite score, where approximately twice as many patients achieved clinically meaningful improvement.

Stroke Common Cause of Seizures, Inebilizumab Demonstrates Continued Benefits, Fremanezumab Safe in Patients With CV Risk

Advantages of Fremanezumab Among CGRP Migraine Agents: Stephanie J. Nahas, MD

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the reasons fremanezumab stands out among a crowded migraine treatment landscape.

Nipocalimab Shows Promise as Myasthenia Gravis Treatment: Jeffrey Guptill, MD, MS, MHS

The associate professor of neurology and neurologist at Duke University discussed the positive results of nipocalimab, a monoclonal antibody, in patients with myasthenia gravis.

Novel Mobile Toolbox Battery Could Improve Cognitive Impairment Detection

The MTB is built to safely, remotely, and effectively collect data from assessments that measure the executive function, language, memory, and processing speed of adults, and can be captured via smartphone.